LATS Young Investigator Awards

Alejandra Dagrosa

Winner 2003


A. Dagrosa *, M. Viaggi*, J. Longhino **, O. Calzetta **, M. Edreira*, R. Cabrini *, G. Juvenal*, M. Pisarev* and ***
Dept. Of Radiobiology, Constituyentes Atomic Center; ** RA-6, Bariloche Atomic Center, CNEA,*** Dept. Of Biochemistry, Univ. of Buenos Aires School of Medicine, Argentina


Undifferentiated thyroid carcinoma (UTC) lacks an effective treatment. Boron neutron capture therapy (BNCT) is based on nuclear reaction 10B(n, a )7Li. These particles destroy the tumor locally due to their high linear energy transfer (LET). In previous studies we have shown that mice transplanted with the human cell line of UTC, ARO have a selective uptake of 10BPA. These results lead us to perform the complete BNCT procedure. Nude mice bearing UTC tumors were treated with BNCT (350 and 600 mg/kg b/w. of BPA). After 35 days of follow-up, we observed that the tumor continued to grow in control and NCT groups. A slow-down in tumor growth was observed in all animals of BNCT (350 mg/kg b/w. of BPA) group and a complete stop of tumor growth in 100% of animals of BNCT (600 mg/kg b/w of BPA) group, while a complete cure was observed in 50% of the mice with an initial tumor volume lower that 50 mm3. The comet assay showed a dose-dependent increased in DNA damage. These data show that UTC is amenable to the treatment by BNCT.